Clinical trial
GALLANT 7 Tesaglitazar Add-on to Sulphonylurea
NCT00251940 · AstraZeneca, Industry · Terminated
Key facts
| NCT number | NCT00251940 |
|---|---|
| Title | GALLANT 7 Tesaglitazar Add-on to Sulphonylurea |
| Official title | A 24-Week Randomised, Double-Blind, Parallel-Group, Multi-Centre, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Tolerability of Tesaglitazar Therapy When Added to the Therapy of Patients With Type 2 Diabetes Poorly Controlled on Sulphonylurea Alone |
| Lead sponsor | AstraZeneca, Industry |
| Status | Terminated |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Type 2 Diabetes |
| Intervention type | Drug |
| Interventions | Tesaglitazar 0.5 or 1 mg, Glibenclamide 2.5, 5, 10 or 15 mg |
| Enrollment | 555 |
| Start date | Jul 1, 2004 |
| Completion | Mar 1, 2006 |
| First posted | Nov 11, 2005 |
| Last update posted | Mar 17, 2008 |
| Countries | Australia, France, Israel, Norway, Philippines, South Africa, South Korea, Spain, United Kingdom, Vietnam |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: